Cancer constitutes a set of diseases with heterogeneous molecular pathologies. However, there are a number of universal aberrations common to all cancers, one of these being the epigenetic silencing of tumor suppressor genes (TSGs). The silencing of TSGs is thought to be an early, driving event in the oncogenic process. With this in consideration, great efforts have been made to develop small molecules aimed at the restoration of TSGs in order to limit tumor cell proliferation and survival. However, the molecular forces that drive the broad epigenetic reprogramming and transcriptional repression of these genes remain ill-defined. Undoubtedly, understanding the molecular underpinnings of transcriptionally silenced TSGs will aid us in our ability to reactivate these key anti-cancer targets. Here, we describe what we consider to be the five most logical molecular mechanisms that may account for this widely observed phenomenon: 1) ablation of transcription factor binding, 2) overexpression of DNA methyltransferases, 3) disruption of CTCF binding, 4) elevation of EZH2 activity, 5) aberrant expression of long non-coding RNAs. The strengths and weaknesses of each proposed mechanism is highlighted, followed by an overview of clinical efforts to target these processes.
Introduction and overview
TSGs code for proteins that restrict the proliferative and survival capacity of a cell. Such genes may be rendered dysfunctional through multiple mechanisms during the oncogenic process. These include mutation, deletion, genetic rearrangement, and epigenetic silencing of transcription. Some TSGs, such as the classic tumor suppressor TP53, are primarily inactivated through mutation. In contrast, other tumor suppressors such as CDKN2A are commonly inactivated through mutation, deletion, or epigenetic silencing. The motivation for cancer cells to challenge the function of some TSGs through multiple mechanisms, while others primarily through a single means, remains unclear. Perhaps this is dependent on the need for a tumor suppressor protein to be expressed for survival, even if it is mutated, rendering it only partially dysfunctional. Alternatively, the position of a gene within the nucleus may dictate the molecular forces influencing the mechanism of inactivation. While environmental carcinogens may inflict mutations in TSGs, the molecular mechanisms whereby gene deletions, rearrangements and epigenetic silencing are initiated is less obvious. It should be noted that there is wide recognition that environmental carcinogens promote the silencing of tumor suppressor genes [1, 2] , but the mechanism delineating precisely how the external environment communicates with the nucleus to propagate silencing of TSGs requires further work.
An important aspect of TSG silencing that is often overlooked is that the process leading to transcriptional shutdown does not rely on a single epigenetic event. Epigenetic silencing is associated with a dynamic reprogramming of the epigenetic code primarily in the promoter region of affected genes. This reprogramming is associated with a loss of activating histone marks (e.g. H3K4me3 and H3K9ac), a loss of histone variants (e.g. H2A.Z), a loss of DNAse I hypersensitive sites, and a gain of several key repressive histone marks (e.g. H3K9me3, H3K27me3), along with hypermethylation of promoter DNA. Thus, a model outlining prospective mechanisms for TSG silencing should, in theory, be able to explain the plethora of changes observed in these regions. Beyond the promoter, DNA methylation is commonly lost from intergenic regions, and much of the genome is hypomethylated. Through understanding the precise mechanism whereby TSG silencing is initiated and maintained, we will undoubtedly identify new targets for anti-cancer therapy. By drugging the epigenetic processes that establish TSG silencing, we might reverse this process as a means to block the growth of primary tumors, or even impede epigenetic silencing before it happens as a means of cancer prevention.
Is the avoidance of TSG silencing really a target for cancer prevention? Evidence suggests that TSG silencing is an early, initiating event in the oncogenic process, and therefore, maintaining expression of these genes may well impede the onset of tumorigenesis. For example, CDKN2A was found to be silenced in the mammary tissue of women at high risk for breast cancer, highlighting the early nature of this oncogenic lesion [3] . Consistent with this, a premalignant zone surrounding a primary breast tumor has been described wherein TSGs are found in a silenced state [4, 5] . In addition to the insight regarding tumor initiation, these studies indicate that the tissue surrounding a primary tumor, often characterized as "normal tissue," is in fact not normal at all. Notably, after surgery and therapy, breast tumor recurrence is commonly observed within a zone proximal to the primary site. It is possible that this premalignant zone encounters further genetic hits (or is genetically unstable), after removal of the primary tumor, accounting for the proximal recurrence. Regardless, these data indicate that intervention aimed at protecting cells from epigenetic silencing of TSGs is a rational means to prevent cancer initiation.
Not only has the silencing of TSGs been correlated with tumor initiation, but with oncogenic progression as well. For example, in melanoma, DNA methylation of a panel of commonly silenced TSGs, including RASSF1A and GATA4 among others, predicts advanced clinical staging and metastasis [6] . Other reports show a similar association between the epigenetic silencing of CDH1 and melanoma progression [7] . These and many other reports indicate reactivating tumor suppressor genes represents a reasonable approach to anti-cancer therapy.
Because TSGs undergo epigenetic silencing in practically all cancers, it is hoped that understanding the molecular mechanisms contributing to transcriptional silencing will also highlight new therapeutic targets to treat a spectrum of malignancies. While this lofty goal has yet to be realized, to date, this theory has been shown to hold some merit, with both DNA methylation and histone deacetylation inhibitors being FDA approved to treat hematopoietic malignancies. There is also strong preclinical data indicating that inhibitors of the chromatin modifying proteins Ezh2 and Brd4 will have some clinical applicability. Drugging the epigenome will be discussed in more detail below.
In this review, we will focus on understanding the mechanisms whereby tumor suppressor gene silencing might be initiated and maintained in cancer cells, highlighting the strengths and shortcomings of each theory. While there may be additional mechanisms than the ones proposed, we cover those models which are both logical, and supported by substantial experimental data. Five models are proposed ( Fig. 1 ): 1) defects in the transcriptional process, 2) overexpression of DNA methyltransferases, 3) dysfunction of CTCF, 4) overexpression of the polycomb protein Ezh2, and 5) aberrant expression of long noncoding RNAs. Overall, we think it is likely that these mechanisms work in concert to initiate, and maintain, the epigenetic silencing of TSGs.
Defects in the transcriptional process
Defects in the transcriptional process may be the most obvious cause of transcriptional silencing, but it is also the most overlooked. We define "defects in the transcriptional process" as molecular perturbations to trans-activating factors, or the core transcription machinery, that impinges on the capacity of RNA Polymerase II (Pol II) to transcribe a target gene. At first glance, there may seem to be a disconnection between the suppression of gene transcription and the acquirement of repressive epigenetic marks, but evidence exists suggesting that this is not the case, and in fact, the two may be tightly linked.
Genome-wide mapping of DNA methylation patterns in Arabidopsis reveals active transcription may shape the DNA methylation landscape [8] . Supporting this study, classic work from the Cedar and Bird research groups using transgenic mouse models both show that mutation of SP1 binding sites leads to a localized accumulation of DNA methylation [9, 10] .
Beyond SP1, other transcription factors have been demonstrated to limit the accumulation of DNA methylation at target genes in multiple types of tissues. Examples of these include the neuronal factor NGFI-A [11] , REST, CTCF, or RFX family members in embryonic stem cells [12, 13] . Importantly, this paradigm seems to have relevance at distal regulatory regions across the genome, where transcription factor occupancy maintains regions of low-density DNA methylation [14] . This interplay Fig. 1 . Schematic highlighting five potential mechanisms utilized during the oncogenic process to silence tumor suppressor genes: 1. overexpression of DNA methyltransferases; 2. overexpression of EZH2; 3. dissociation of CTCF from chromatin boundaries; 4. loss of transcription factor binding; 5. aberrant expression of long non-coding RNAs. Green circles represent "activating" epigenetic marks such as histone acetylation, or H3K4me3. Red circles represent repressive histone modifications such as H3K27me3 or H3k9me3. Gray circles represent DNA methylation.
between transcription factor binding and DNA methylation appears to be quite complex. For example, it has been shown that de novo methylation outcompetes NRF1 binding and that the NRF1 site itself does not act as a shield against localized DNA methylation [15] . But deletion of NRF1 flanking sites for factors including CTCF, or RFX, does lead to a significant gain of DNA methylation indicating transcription factors act as a barrier against the activity of DNA methyltransferases (DNMT). It is also possible that the transcriptional activity of Pol II itself may act as an important means to restrict DNA methylation. One of the shortcomings of these studies is that the relationship between transcription factor binding and Pol II recruitment is often not clearly delineated. One scenario not accounted for by these studies is that the loss of transcription factors critically involved in Pol II recruitment will result in subsequent DNMT recruitment because of the loss of Pol II itself. In contrast, the loss of factors acting on other steps of transcription, such as elongation, would not result in increased DNA methylation.
Recently, a seminal paper from the Heinlein lab revealed that pharmacological blocking of Pol II mediated transcription with DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole) leads to an accumulation of the repressive histone modification H3K27me3 [16] . This finding suggests that active transcription may be required to prevent the accumulation of marks that promote and maintain epigenetic silencing. The accumulation of other classic modifications associated with heterochromatin such as DNA methylation, and H3K9me3, were not probed for in this setting. Nonetheless, these data raise the interesting possibility that the loss of transcription factor binding to target genes, resulting in inactivation of transcription, may, in turn, promote the accumulation of repressive histone modifications.
A question arising from this body of work is, "What are the molecular defects that compromise transcription factor binding in cancer"? Obviously, mutation can impact protein-DNA associations, but are there other driving forces? Transcription factor binding is intricately linked to signaling cascades from receptor tyrosine kinases (RTKs). Hyperactivation of such signaling pathways is a driving force in many malignancies. Intriguingly, activation of oncogenic drivers such as KRAS or HER2 are associated with precise patterns of DNA methylation [17] [18] [19] . While the mechanism for this association remains ambiguous, it is possible that constitutive activation of signaling cascades disturbs transcription factor binding in a predictable fashion, leading to defined patterns of altered DNA methylation. As an alternative explanation, these oncogenic drivers may also influence the other mechanisms of silencing we describe below.
Our conclusion from these studies is that the loss of transcription factor binding represents a rational yet understudied mechanism whereby the expression of tumor suppressor genes may be lost in cancer. One envisions that the loss of a transcription factor critical for the trans-activation of multiple TSGs could reasonably result in the concurrent epigenetic deregulation that is observed in so many tumors. It would be interesting to carry out ChIP-seq profiling of tumors to assess whether loss of transcription factor binding is indeed associated with transcriptional silencing. Further, it is clear that more work needs to be done using pharmacological inhibition of Pol II with such agents as flavopyridol and α-amanitin, coupled with knockdown experiments and mutation of transcription factor binding sites, to establish that transcription is truly antagonistic to the accumulation of repressive epigenetic marks.
Initiation and maintenance of epigenetic silencing by DNA methyltransferases
Eukaryotic DNA is commonly methylated on the 5th atom of cytosines residues in the dinucleotide sequence CpG. In vertebrates, DNA methylation is mainly mediated by three enzymes: DNMT1, DNMT3a, and DNMT3b. DNMT1 is referred to as a maintenance DNA methyltransferase. The strong affinity of DNMT1 for hemimethylated DNA, and interaction with PCNA, ensures that daughter strands obtain a correct DNA methylation profile during replication. DNMT3a/b principally act as de novo methyltransferases, and it is these family members which are thought to play a major role in mediating the epigenetic silencing of tumor suppressor genes in cancer.
Across the majority of the genome, CpG sites are underrepresented and heavily methylated. In contrast, there are at least two discrete regions of the genome where low-density DNA methylation is found. The first, called "CpG islands," are loci defined by an enrichment for CpG dinucleotides at much higher frequency than found randomly throughout the vast majority of the genome. These islands are usually associated with gene promoters and are distributed in a non-random manner to generate a pattern of DNA methylation that is site-, tissue-, and gene-specific. CpG island DNA methylation is strongly associated with transcriptional silencing and maintenance of CpG islands in an unmethylated state is important for gene activity. Promoter DNA methylation is generally considered to be the culminating step in the silencing process, with repressive histone modification facilitating subsequent DNA methylation, resulting in long-term, often irreversible, shutdown of transcription [20, 21] .
In addition to CpG-rich promoters, enhancer regions also represent a region of low-density DNA methylation [22] . Enhancers are key transcriptional elements ensuring proper tissue-specific gene expression. Hypomethylated enhancers allow trans-activating factors to bind and promote transcriptional elongation of corresponding target genes.
The normal pattern of genomic DNA methylation is dramatically altered during neoplastic transformation. There is a reversal of this methylation across much of the genome from a heavily methylated landscape to a hypomethylated state especially at intergenic regions [23] [24] [25] . It has been proposed that decreased DNA methylation in repeat sequences promotes genomic instability such as chromosomic deletions and translocations [26] [27] [28] . Conversely, an aberrant gain of DNA methylaton at the CpG islands and enhancer regions of critical tumor suppressor is observed in most, if not all, cancers. For example, the promoter DNA of some key tumor suppressors, such as CDKN2A and RASSF1a, controlling cell cycle and apoptosis, is hypermethylated in a broad spectrum of cancers and premalignant tissues. However, a gain of DNA methylation at enhancers may be a more significant mechanism of gene silencing in cancer than the hypermethylation of promoter DNA [29, 30] .
Cancer cell lines were first shown to harbor highly elevated DNA methyltransferase activity relative to normal cells in the 1980s by the group of Peter Jones [31] . In another landmark paper, the same group later demonstrated overexpression of DNMT3b in tumors [32] . Many other reports have substantiated these findings in multiple cancers [33, 34] . Clearly, there is a selective pressure to up-regulate DNA methyltransferase activity in cancer cells, and DNMT3b up-regulation in particular promotes tumor progression in murine colorectal models through silencing SRFP tumor suppressors [35] . Moreover, DNA methylation may affect oncogenic progression not only by acting on gene expression but also by increasing the mutation rate of methylated cytosines, compared to unmethylated residues [36] . But is DNMT3a/b overexpression necessary or sufficient for the silencing of most tumor suppressor genes? Alternatively, do DNMTs work in concert with the other mechanisms proposed herein to induce gene silencing?
There is much evidence that DNMT expression maintains epigenetic silencing of key TSGs [37] [38] [39] [40] . For example, knockdown of DNMT1 in tandem with DNMT3b reactivates one of the most common epigenetically silenced genes, CDKN2A [39] . The initiation of silencing can be considered a separate event from maintenance. It has not been firmly established that simple overexpression of DNMTs can initiate the silencing of TSGs, but there is at least some evidence supporting such a role [41] . For example, using a transgenic mouse model of colorectal cancer, it was demonstrated that overexpression of DNMT3b leads to changes in gene profiling congruent to what is observed in human colorectal cancer [42] . However, overall, there is a lack of direct evidence that simple overexpression of DNMTs initiates gene silencing in cancer. It is thought that DNMT3a/b must be targeted to CpG islands by secondary factors, including H3K9me3 modification, or via binding to transcription factors. Independent model systems predict epigenetic modification of histones with repressive marks, especially H3K9me3, precedes DNA methylation [21, 43] . There is even evidence in vitro that cells pressured to transform through ectopic overexpression of DNMT3b will first turn off transcription of key tumor suppressors through acquirement of repressive covalent histone modifications (H3K9me2 and H3K27me3) prior to acquisition of DNA methylation [2] .
In addition to epigenetic marks, DNMTs may be recruited to target genes via interactions with a variety of transcription factors [44] . PU.1 and MYC, in particular, represent examples of transcription factors that may aberrantly target DNMT3b to the promoters of classic tumor suppressor genes leading to gene silencing [45, 46] . The idea that recruitment to promoter regions initiates silencing is supported by a recent paper showing that DNA methyltransferase activity targeted to the CDKN2A promoter using engineered zinc fingers, results in complete silencing of the gene [47] . Interestingly, genome-wide surveys of DNMT localization find that DNMTs are commonly found at actively transcribed loci [48] . Based on these data, it was postulated that disruption of chromatin boundaries (also described herein) may broaden the DNA territory targeted by DNA methyltransferases, leading to promoter silencing [48] . Supporting this concept, chromatin boundaries themselves may act as focal points to recruit PARP1, whose enzymatic action has been shown to suppress DNMT1 methyltransferase activity [49, 50] .
In general, tumor suppressors are epigenetically silenced in a higher percentage of tumors than those showing aberrant DNMT overexpression, necessitating additional mechanisms of silencing. Clinically, if DNMTs are initiating down-regulation of tumor suppressor gene transcription, one would expect to see a strong correlation between high DNMT expression and shutdown of TSGs. However, this link has been wildly variable. The first study to explore the relationship focused on colorectal cancer and failed to see a relationship between DNMT3a/b expression and DNA methylation of APC, ESR1, p16, or MLH1 promoters [51] . Similar absences of such a correlation has been reported for cancers of the breast [34, 52] , lung [53] [54] [55] , prostate [56] , liver [57] , stomach [58] , and myelodysplasia [59] . In stark contrast, conflicting reports claim there is indeed a correlation between high DNMT levels and hypermethylation of TSGs, in many of the same tumors listed above [60] [61] [62] [63] [64] . It is difficult to draw conclusions from such divergent studies. Most of these clinical studies merely examined a small subset of genes found hypermethylated in each individual cancer. If larger cohorts of methylated promoters were examined, then stronger correlations might be identified.
Mechanistically, DNMT overexpression is likely to play an important role in the concurrent silencing of many tumor suppressor genes. Still, key questions remain. In tumors where DNMTs are not highly expressed, what mechanisms can explain the silencing? Is aberrant transcription factor binding necessary to recruit DNMT3b to TSGs? Large stretches of the genome become hypomethylated during tumorigenesis and hyperactive DNA methyltransferase activity cannot account for this phenotype in an obvious manner. We now proceed to explore other mechanisms of silencing that may work in concert with, or in lieu of, DNMT overexpression.
Loss of CTCF binding disrupts epigenetic boundaries
Epigenetic silencing of tumor suppressor genes is not an isolated event. Within any given tumor, several, if not many, TSGs are transcriptionally silent. Even within hyperplasia, or normal tissue of patients at high risk for cancer, multiple genes regulating proliferation or survival can be found shut down. While TSGs are often concurrently silenced, it is unclear if shared, or independent mechanisms are in place to coregulate these genes. If these genes were indeed coregulated, a single genetic aberration might explain their concurrent silencing. One such explanation could reside in coregulation by the epigenetic regulatory protein CTCF.
CTCF was first described as a transcriptional repressor of the MYC gene, but subsequent knockdown studies reveal CTCF primarily plays a role in gene activation [65, 66] . CTCF may impact gene expression at multiple levels including modulating Pol II activity directly, or via organization of tertiary chromatin structure. CTCF interacts with several transcription factors and even components of Pol II itself [67] [68] [69] . Thus, CTCF may influence transcription directly via recruitment of Pol II subunits or by promoting transcriptional initiation.
Elegant genome-wide chromosomal interaction studies have revealed a complex role for CTCF in mediating inter-and intrachromosomal attachments. The anchor points for these attachments have now been shown to be enriched for Pol II occupancy, consistent with the reports outlined above suggesting an interplay between CTCF and Pol II activity [70, 71] . CTCF facilitates such long-range cis and trans interactions through the formation of homodimers, bringing multiple CTCF sites in contact with one another, or alternatively, in collaboration with the cohesin complex. Connections in cis result in chromatin looping, with shorter loops being assembled within large loops [72] . The orientation of the CTCF-binding sites anchoring chromatin loops strongly influences their assembly, with the majority of CTCF anchor sites oriented in a convergent fashion [70, 73] . While more functional studies are warranted, there is evidence that chromatin loops mediated by tandemly arranged CTCF sites may coordinate promoter-enhancer interactions [73] .
The largest of these loops define chromatin domains, within which, cis connections are made, but not to sites outside this topologically associating domain (TAD) [72] . The CTCF-binding at the 5′ and 3′ limits of these TADs can act as an insulator, preventing aberrant connections between adjacent TADs. Not only do these boundaries act as insulators, but they are also able to act as classical "chromatin boundaries," partitioning distinct epigenetic domains [74] . Historically, these boundaries are thought to prevent the spread of heterochromatin, which is considered to be the "default state" [75] [76] [77] . There is a considerable body of work supporting a role for CTCF in maintaining chromatin boundaries in order to prevent the spread of repressive heterochromatin [78] [79] [80] [81] . One compelling example is provided by the group of Recillas-Targa, who show that a CTCF boundary constrains the spread of heterochromatin at the FOLR1 gene [82] . During the course of erythroid differentiation, CTCF binding is displaced, with a concomitant spread of repressive chromatin (DNAse I resistant) and gene repression ensuing. A recent seminal discovery from the Reinberg research group muddies this paradigm [83] . Therein, they clearly demonstrate, via genome editing, that the loss of a CTCF boundary actually leads to aberrant spreading of histone modifications associated with euchromatin and actively transcribed genes.
Functional studies of long-range chromatin connections are in its infancy and many key questions are yet to be answered. Future studies will need to examine whether CTCF protein involved in mediating these interactions also plays an active role in regulating nearby genes, or recruits histone-modifying enzymes. It is also unclear precisely how boundaries prohibit the spread of histone modifications. Mutation of CTCF sites in vivo and in vitro results in local accumulation of DNA methylation [84, 85] , but it is unclear if this is associated with disruption of long-range interactions. Not all CTCF sites mediate long-range associations, indicating CTCF truly is a multifunctional protein with roles beyond establishing DNA interaction in cis and trans.
CTCF binding is observed throughout the genome but may become disassociated from key sites in cancer cells [86] [87] [88] [89] [90] [91] (Table 1 ). This loss of binding has yet to be confirmed directly from tumor samples. Disruption of CTCF binding has been correlated with down-regulation of tumor suppressor genes and aberrant accumulation of repressive histone modification and DNA methylation. It is thought that the lack of CTCF binding releases repressive chromatin modification from the constraints imposed by chromatin boundaries, allowing them to spread passively into the promoter regions of nearby genes effectively shutting down their transcription. Related to this idea, it has also been demonstrated that CTCF is important for maintaining DNA methylation-free regions [86] . It is possible that CTCF boundaries act as focal points for PARP1 recruitment, and it is actually the localized accumulation of poly(ADP-ribose) polymers that prohibits DNMT1 methyltransferase activity in these regions of the genome [49, 92] .
Lamina-associated domains (LADs) are repressive chromatin domains tethering chromosomes to the nuclear periphery. Independent reports indicate the massive domains of DNA hypomethylation found in cancer are enriched at LADs [24, 93] . Notably, LADs are generally insulated by CTCF [94, 95] . Taken together, it is tempting to speculate that disruption of CTCF binding reorganizes LADs and the spatial distribution of chromatin within the nucleus, leading to aberrant patterns of DNA methylation.
CTCF may also be related to genome-wide DNA methylation patterns through interplay with the histone variant H2A.Z [96] . CTCF positions an array of 20 nucleosomes around each binding site, with the array being enriched for the histone variant H2A.Z. In Arabidopsis, and Puffer fish, H2A.Z placement is anti-correlated with DNA methylation [97, 98] and loss of proper H2A.Z positioning results in genome-wide accumulation of DNA methylation [97] . This is consistent with mammalian data indicating H2A.Z is often enriched at euchromatic regions of the genome, especially promoter and enhancer regions [99] . Notably, knockdown of CTCF by shRNA, RNAi, or conditional knockout leads to loss of H2A.Z incorporation at CTCF regulated genes [88, 100] . Thus, we might extrapolate that displacement of CTCF from cognate binding sites leads to a loss of H2A.Z and destabilization of chromatin boundaries, culminating in a deregulated accumulation of DNA methylation.
CTCF binding to a subset of DNA elements is known to be disrupted by DNA methylation of CpG motifs found within its cognate DNA-binding element [101] . This leads to a "chicken and egg" scenario where it is unclear whether loss of CTCF is the initial event, leading to accumulation of proximal DNA methylation, or alternatively, whether spurious DNA methylation events displace CTCF, which would indicate a role in the maintenance of silencing, rather than initiation. There are data supporting a direct, or causal, role for CTCF in opposing the accumulation of repressive epigenetic marks. Elegant in vitro and in vivo studies demonstrate that disruption of CTCF-binding sites within cells, such that the protein can no longer bind, will indeed lead to the localized accumulation of repressive epigenetic marks including DNA methylation [78, 84, 85, 102] . These studies have been complemented with work using CTCF knockdown leading to similar conclusions [87, 100] .
How is CTCF binding disrupted in cancer? There are at least five possible mechanisms, and perhaps more to be discovered. First, CTCF-binding sites can be found mutated, prohibiting CTCF binding [91] . Second, CTCF itself is mutated in a spectrum of cancers, notably at 18% or higher in endometrial cancers [103] . Overall, the impact of these mutations on CTCF function is awaiting clarification, but several of the mutations identified within the DNA binding domain disrupt its binding to the promoters of several tumor suppressor genes in vitro [104] . Third, loss of the post-translational modification poly(ADP-ribosylation) from CTCF has been detailed in breast tumors [105] . In Drosophila, such a loss of poly(ADP-ribosylation) results in a release of a fraction of total CTCF from chromatin [106] . Fourth, the association of CTCF with noncoding RNAs is important for its organization into multimers [107] . CTCF homodimers are important for establishing intra-chromosomal contacts and chromatin boundaries. Thus, the dissociation of CTCF from these RNAs, either through mutation or other means, could very well lead to a disruption of chromatin boundaries and gene silencing. Finally, there is evidence that CTCF may be targeted to a subset of promoters by protein cofactors [68, 69] . Disruption of such an interaction, while not described in tumors, would lead to ablation of CTCF binding at these target genes.
Within tumors, TSGs are not silenced as solo events, but multiple silencing events are often concurrent. Similarly, aberrant epigenetic changes at these genes are not confined to a single modification, but a reversal of an entire spectrum of modifications is observed. The disruption of a single CTCF site can, in fact, explain both of these phenomena in perhaps a more satisfying manner than other proposed mechanisms of silencing. As outlined above, CTCF mediates long-range chromatin interactions, including those between non-homologous chromosomes. Therefore, in theory, the loss of a single CTCF site could impede the transcription on neighboring chromosomes, resulting in a network of silencing that could even trigger a chain event of silencing. Further, ablation of a chromatin boundary maintained by CTCF will result in the passive spread of epigenetic modifications found flanking the boundary [71] . One envisions that a wave of heterochromatin might encroach upon tumor suppressor genes if proximal boundaries were compromised.
A major weakness of the CTCF hypothesis is the lack of clinical validation. It remains to be seen whether CTCF binding is really lost from epigenetically silenced genes in tumor samples, or if this is simply an artifact of tissue culture. Future ChIP analysis of frozen tumor specimens will be key for validation. Finally, CRISP/Cas9 manipulation of CTCF binding sites is needed to assess the notion of concurrent silencing, and whether loss of individual CTCF sites near tumor suppressors does indeed disrupt boundaries leading to a spread of heterochromatin marks.
Transcriptional repression by EZH2 overexpression
Members of the polycomb group (PcG) genes were identified 60 years ago in Drosophila melanogaster as regulators of Hox gene clusters. Because mutation of PcG proteins resulted in activation of Hox gene expression, PcG were accurately classified as repressors [108] . PcG proteins are organized into two complementary complexes. Polycomb repressive complex 1 (PRC1) and PRC2. PRC2 has protein methyltransferase catalytic activity mediated by the EZH2 subunit [109] . EZH2 covalently modifies Histone 3 on lysine 27, placing a trimethylated tag (H3K27me3) that negatively impacts transcription [110] . H3K27me3 is in turn recognized primarily by the CBX2 subunit of the PRC1 complex [110] . Once recruited to promoters via H3K27me3, the PRC1 complex represses transcription by prohibiting Pol II occupancy [111] , possibly through occlusion of key members of the preinitiation complex [112] . Notably, PRC1 is now known to be recruited to genes via association with non-coding RNAs (reviewed below).
EZH2 has been clearly demonstrated to possess oncogenic properties [113] , is commonly overexpressed in a variety of malignancies, and has been correlated with poor overall survival. Supporting its role as an oncogene, somatic, activating EZH2 mutations are thought to be an oncogenic driver of DLBCL. Under physiological conditions, EZH2 is a key regulator of many TSGs found silenced in cancer [114] , and it is generally understood that EZH2 promotes oncogenic progression through the silencing of tumor suppressor genes [115] . Interestingly, there are data indicating TSGs targeted for epigenetic silencing in cancer [114, 116, 117] . Thus, during the oncogenic process, this mark somehow predisposes genes for further repressive programming. Knockdown of EZH2 revealed that it plays an important role in proliferation, specifically through advancement of the cell cycle. However, it is possible that EZH2 harbors oncogenic functions beyond its ability to catalyze the transfer of methyl groups onto histones [118] . Therefore, EZH2 may control cell cycle progression via mechanisms independent of its capacity to silence TSGs. As mentioned above, the promoters of TSGs epigenetically silenced invariably display enrichment for H3K27me3. But is this mark an initiator of silencing, important for maintenance of long-term silencing, or does it somehow aberrantly target these genes for DNA methylation specifically in cancer cells? Regarding the mechanism of initiation, there is indeed evidence that EZH2 represents an important piece of this puzzle. We know that epigenetic silencing is an early event during oncogenesis. Two reports find EZH2 overexpression in premalignant tissue of the lung [119] and breast [120] , consistent with EZH2 playing a key role in such silencing. EZH2 has also been shown to directly repress the expression of classic tumor suppressor genes such as CDKN2A [121] and RARβ [122] (for a list of targets, see Table 2 ). It is unclear how overexpression of EZH2 results in precise targeting of the PRC2 complex to transcriptionally active promoters. Further, it is unclear that ectopic expression of EZH2 leads to an accumulation of repressive epigenetic marks such as H3K9me3 and DNA methylation that are observed at TSGs within tumors.
If EZH2 plays a role in the maintenance of epigenetic silencing, then knockdown of EZH2 might be expected to restore the expression of targets, and there should be a correlation between elevated EZH2 and DNA hypermethylation of TSGs. Knockdown, or pharmacological inhibition of EZH2, does increase the expression of TSGs such as CDKN2A and CDKN1A [117, 123] , but it is unclear that loss of EZH2 activity will reactivate genes whose promoters are enriched for DNA methylation [124, 125] . Even if knockdown of EZH2 cannot overcome the epigenetic lock set in place by DNA methylation, it is possible that EZH2 contributes to the initiation of silencing, leading to the further epigenetic reprogramming that is commonly observed at silenced tumor suppressor genes, culminating in DNA methylation. It is clear that targeting polycomb proteins to the promoters of tumor suppressor genes, such as Rassf1a, does indeed lead to transcriptional repression [126] , but does this lead to subsequent reprogramming [127] ? The relationship between PcG target genes and DNA methylation is complex and more study is needed before it is completely understood. Certainly, in stem cells, bivalent domains are well characterized, with regions of H3K27me3 and H3K4me3 coexisting without further accumulation of repressive marks. Similarly, in AML blasts, H3K27me3, as well as EZH2, is seen to extend throughout the INK4a (comprising CDKN2A and CDKN2B genes) locus irrespective of the DNA methylation status of the gene [128] . At silenced TSGs in cancer cells, H3K27me3 and DNA methylation invariably co-occur. There is indication that the CBX7 subunit of PRC1 may bind and recruit DNMT1 or DNMT3b [129] . Is it possible that overexpression of specific PcG subunits in cancer leads to aberrant recruitment of DNMTs to TSGs in cancer cells?
Clinically, it is firmly established that EZH2 is oncogenic and corresponds with disease progression in a number of cancers [130, 131] . However, it is unclear that a strong correlation exists between EZH2 overexpression and the silencing of TSGs, but EZH2-mediated silencing may be through tissue-specific mechanisms [56, 128, [132] [133] [134] [135] [136] . Consistent with the idea of tissue-specific effect on gene silencing, TCGA data indicate EZH2 levels are inversely linked to the repression of a GSTP1, RARB, and TIMP3 in prostate cancer, but this is not observed within breast tumors (Fig. 2) . As is the case with DNMTs, most studies attempt to draw correlations between EZH2 overexpression and the DNA hypermethylation and silencing of only a small number of handpicked genes. Genome-wide profiling will be necessary to draw stronger correlations.
An interesting development in the field of EZH2 biology is the finding that PcG proteins work in a coordinated fashion with non-coding RNAs to silence target genes. This concept helps fill an important gap in our knowledge regarding the recruitment of polycomb complexes to specific loci.
Non-coding RNAs
Non-coding RNAs have firmly established themselves as major players in the field of cancer biology. Until recently, the spotlight has been primarily on the role of small RNAs (microRNAs (miRNA), endogenous small interfering RNAs (siRNAs), and PIWI-associated RNAs (piRNAs)) in cancer. Recently, however, the long non-coding RNAs (lncRNAs) have received considerable recognition for their contribution toward multiple aspects of tumor growth and cancer progression [137] . Fig. 2 . Inverse correlation between EZH2 expression and the repression of tumor suppressor genes is tissue-specific. Expression data from "The Cancer Genome Atlas" was analyzed across seven tumor types to compare EZH2 expression with known target genes, commonly silenced in cancer. An inverse correlation between the mRNA levels of these five tumor suppressor genes and EZH2 is most apparent in cancers of the prostate, lung, stomach, and liver, but less so in pancreatic and breast cancer.
After the completion of the genome project and the consequent analysis of the results, it has been estimated that of the 70% of DNA actively transcribed, only 1.2% of the human genome codes for proteins [138] . Further analysis revealed an abundance of long non-protein-coding antisense transcripts [139] . lncRNAs are 200 or more nucleotides long and are transcribed either from intronic sequences, intergenic regions, or from the opposite strand of the protein-coding gene, producing antisense transcripts. Due to their size, they have a propensity to form secondary and higher-order structures [140] . The architecture of the lncRNA is inextricably linked to its function. For example, the proper folding of MEG3 lncRNA is key for modulating the p53 tumor suppressor activity [141] . Moreover, lncRNAs may alter their structure and adopt different stable conformations, which allows them to regulate multiple processes, interacting with DNA, RNAs, and proteins [140] . It is thus not surprising that they might play an important role in cancer, affecting most of the recognized hallmarks of the disease [137] .
With respect to the regulation of TSGs, aberrant increases of lncRNA levels may impact TSG transcription through multiple mechanisms [144] . The lncRNAs can form RNA-protein complexes with DNMT3a [145] , PRC2 [146] and H3K9 methyltransferases [147] , and recruit these complexes to specific sites, enabling transcriptional repression. This is achieved by newly synthetized lncRNAs tethering repressive complexes, thus enabling in cis silencing of genes in the vicinity of the lncRNA transcription site. Alternatively, lncRNA transcripts can leave their transcription sites and bind to other RNAs or proteins and guide them to various genomic locations, thus facilitating the transcriptional repression in trans [142, 148] . In addition to recruiting specialized complexes to the chromatin, lncRNAs also act as decoys for miRNAs thereby attenuating their ability to silence the transcript targets [144] . One of the strengths of the idea that aberrant activation of lncRNAs represses tumor suppressor genes is that their capacity to act in trans [142, 143] would enable them to concurrently silence TSGs that are often seen co-silenced in cancers (for a list of target genes, see Table 3 ).
Remodeling the epigenome plays a crucial role in tumorigenesis [149] . Strikingly, it has been shown through RIP-ChIP assays that at least 38% of lncRNAs associate with chromatin remodeling complexes, and approximately 20% bind to PRC2 [148] . Polycomb complexes may repress chromatin via two distinct mechanisms: first, through trimethylation of H3K27 and monoubiquitination of histone H2A. The lncRNAs guide and tether the polycomb repressive complexes (PRC1/2) to specific genomic regions for epigenetic silencing [150] . This interaction, in particular, may have important implication in the tumorigenic process. This concept is expanded upon below, with additional examples illustrating critical lncRNA-chromatin interactions and their relevance to cancer.
Some of the most commonly silenced TSGs in cancer are targeted and repressed by lncRNAs. ANRIL, an antisense non-coding RNA transcribed from the INK4 locus, is a well-characterized lncRNA that binds to SUZ12 and recruits the PRC2 complex in cis to the CDKN2A and CDKN2B genes transcribed from this locus, which in turn methylates H3K27 resulting in gene repression [151, 152] . Likewise, depletion of ANRIL increases expression of the CDKN2B gene and decreases cell proliferation [151] . Precisely which polycomb subunit binds ANRIL is disputed. With one study showing interaction with the SUZ12 subunit of PRC2 [151] , while a second study indicates ANRIL recruits polycomb through interaction with the CBX7 subunit of PRC1 [152] . It is likely that non-coding RNAs may in fact target multiple subunits of the PRC1/2 complexes [153] , but most studies indicate an interaction with PRC2 members [148] .
A recent study indicates that expression of ANRIL is elevated in the non-small cell lung cancer (NSCLC) and is associated with a poor prognosis of the overall survival [154] . A more global approach using genome-wide association studies (GWAS) shows that ANRIL is among the susceptibility loci for breast cancer and glioma [155, 156] . While the mechanisms for these clinical studies were not defined, it is likely mediated, at least in part, through aberrant recruitment of repressive epigenetic marks.
In a similar manner to ANRIL, an intronic lncRNA called ANRASSF1, expressed in the RASSF1 tumor suppressor gene locus, recruits SUZ12, which, in turn, increases the H3K27me3 level at the promoter region of RASSF1A isoform [126] . This lncRNA promotes cell proliferation in vitro and is highly expressed in breast tumors, as well as breast and prostate cancer cell lines [126, 157] .
It is also proposed that ANRIL down-regulates miR-99a/miR-449a via PRC2, specifically through SUZ12 binding and H3K27 trimethylation of the miR-99a/miR-449a promoters [158] . These miRNAs are putative tumor suppressors that keep cell proliferation and cell cycle progression in check via repression of the mTOR and CDK6/E2F1 pathways [158] . In the same study, authors show that the knockdown of ANRIL reduces gastric cancer cells proliferation in vivo, thereby suggesting its important role in tumorigenesis. The above examples highlight the ability of lncRNAs to methylate DNA via recruiting PRC2 either in cis or in trans, as in the case of the silencing of the miR-99a/miR-499a distant loci. Although most of the chromatin remodeling properties of lncRNAs are attributed to their interactions with the PcG, there is evidence that at least one of the lncRNAs, HOTAIR, also binds to the lysine-specific demethylase 1 (LSD1) thus recruiting the LSD1/CoREST/REST together with PRC2. In this manner, HOTAIR coordinates gene silencing by scaffolding both the PRC2 and the LSD1/CoREST/REST and allowing for histone modifications to take place [153] . There is currently little evidence that HOTAIR contributes to cancer initiation via this interaction, but we know that HOTAIR is deregulated in a variety of cancers, its heightened expression correlates with tumor progression including increased invasiveness [159] , metastasis [143] , and proliferation [160] . Not all lncRNAs act to repress chromatin. The lncRNA HOTTIP has been shown to activate oncogenes in cis at the HOXA cluster through recruitment of the WDR5/ MLL complex [161] . It is reasonable to think that there is selective pressure for cancer cells to aberrantly activate both of these lncRNAs, and it is an intriguing idea that HOTAIR and HOTTIP may act in concert to stimulate oncogenic progression.
Finally, there are also instances when the lncRNA can directly bind to the DNA and act as a silencer. In the case of the dihydrofolate reductase (DHFR), the gene has alternative promoters, and the transcript of the minor upstream promoter maintains transcriptional repression of the major promoter of DHFR, thus down-regulating its gene expression in quiescent cells [162] . Key questions regarding the role in lncRNA in the epigenetic silencing of TSGs still persist. Do lncRNAs reprogram the epigenetic landscape of gene promoters beyond H3K27me3? Do they promote subsequent DNA methylation? There is also scant clinical evidence of correlations between lncRNA expression and the epigenetic silencing of TSGs in human tumors. Since lncRNAs appear to promote late-stage oncogenic events, can they account for the epigenetic silencing of tumor suppressors apparent in early neoplastic lesions? Future work will hopefully shed light on these provocative questions.
Clinical potential
The reversible nature of epigenetic modifications makes them attractive anti-cancer therapeutic targets. Reactivation of epigenetically silenced TSGs presents a challenging goal because of the complexity of events initiating and maintaining the silenced state. Decades of work aimed at understanding the basic mechanisms associated with epigenetic process and their deregulation in cancer have now yielded a bounty of pharmacologic agents capable of restoring the expression of silenced genes, or shutting down oncogenes. Currently, a spectrum of epigenetic drugs are in clinical trials including histone deacetylase inhibitors, histone demethylase inhibitors, DNA methyltransferase inhibitors, and bromodomain inhibitors. Here we will discuss nucleoside analogs, EZH2 inhibitors, and HDAC inhibitors, therapies targeting the processes described above, with the goal of re-expressing silenced TSGs (Fig. 3) . The first of this class of inhibitors to be developed, and most broadly tested in clinical trials, are the DNA methyltransferase inhibitors.
Nucleoside analogs
The most clinically relevant DNMT inhibitors developed to date are cytidine analogs that incorporate into DNA, thereby blocking the catalytic actions of DNMTs, but also triggering their degradation [163] . 5-aza-2′-deoxycytidine, or decitabine, is a nucleoside analog currently being tested in over 70 active clinical trials. The outcome of exposure to decitabine includes reversal of abnormal promoter DNA methylation, and repressive histone modification leading to the re-expression of silenced genes, including tumor suppressors, and changes in cancer signaling pathways like apoptosis, cell cycle, or stem cell self-renewal [164] [165] [166] . Notably, two recent reports indicate the primary antiproliferative effect of nucleoside analogs is through activation of an antiviral response mediated by transcription of endogenous repetitive elements [167, 168] . These data are consistent with many preclinical studies demonstrating nucleoside analogs potentiate an active immune response [169] [170] [171] [172] . These findings lead to the emerging possibility of using epigenetic therapy to prime patients with solid tumors to immunotherapy, and clinical trials are underway to test this concept in NSCLC (NCT01928576).
Decitabine has a favorable toxicity profile [173] and, thus far, is FDAapproved for the treatment of myelodysplastic syndromes (MDS) and chronic myelomonocytic leukemia (CMML). Decitabine has proven to increase survival in responsive patients with high-risk MDS, but the duration of the response is temporary and only 40-50% of patients responded [174, 175] . New nucleoside analogs such as zebularine have a reduced toxicity profile, and greater bioavailability, which may allow a broadened use of this drug [176] . While myelosuppression may be a clinically important goal for reducing cancer stem cells of the bone marrow, myelosuppression leads to increased susceptibility to infection. This severe toxicity may limit the utility of this class of compounds [177] .
In theory, reactivating tumor suppressor genes is a logical means to ablate the uncontrolled proliferative and survival capacity of cancer cells. Why are nucleoside analogs not more effective clinically? Modern Fig. 3 . Overview outlining the epigenetic action of epigenetic therapies aimed at restoring the expression of TSGs. Nucleoside analogs have been proven to reactivate TSGs and partially reprogram the epigenetic code to a more physiological state. The impact of EZH2 inhibitors on epigenetic modification beyond H3K27me3 is awaiting clarification. medicine has revealed molecular subtypes for many common cancers. Currently, there is a shift toward personalized cancer therapy, where specific pathological subtypes are targeted with precision drugs. The lack of such molecular biomarkers to predict response to nucleoside analogs may help explain why agents such as decitabine have had limited clinical impact on cancers beyond MDS/CMML. Further, recent reports showing DNMT inhibition activates not only the transcription of tumor suppressor genes but also LINE and SINE repetitive elements highlight the non-specific nature of these agents [167, 168] . It possible that an unwanted effect of nucleoside analogs is the activation of epigenetically silenced oncogenes or pluripotency genes that might limit their anti-cancer potential [178] [179] [180] .
A new generation of DNMT inhibitors (non-nucleoside agents) have been developed with the hope of improving drug potency, and specificity due to their higher selectivity [181, 182] . Specific DNMT inhibitors might also be amenable to discovery of predictive biomarkers. Each DNMT isoform may be overexpressed in particular types of cancer. For example, overexpression of DNMT3b is common in acute myeloid leukemia [183] and breast cancer [34] , while DNMT3a levels remain stable. Non-nucleoside agents targeting a specific isoform might address the issue of "over-targeting."
Intriguingly, IDH1/2 mutations may act as a novel biomarker to predict the efficacy of nucleoside analogs. IDH1/2 mutations are frequent events in a number of difficult to treat cancers including glioma and cholangiocarcinoma. IDH1/2 mutations result in an altered enzymatic activity leading to the production of the onco-metabolite 2-hydroxyglutarate (2HG) [184] . 2HG acts as a competitive inhibitor of α-ketoglutarate-dependent dioxygenases. A number of such enzymes help shape the epigenome, specifically, through demethylation of both target histones and DNA. An important recent study showed that IDH mutation leads to an aberrant increase in DNA methylation at chromatin boundaries, due to the inactivation of TET-mediated DNA demethylation [185] . Such DNA methylation was prohibitive to CTCF binding, allowing activation of oncogene transcription through aberrant enhancer promoter contacts. Exposure to 5-azacytidine restored CTCF binding and abrogated the expression of the oncogenic driver, PDGFRA. Of course, further work needs to be done to define whether disruption of key insulator elements truly predicts sensitivity to nucleoside analogs, or combination therapies with this class of drugs. But this work underscores the importance of uncovering molecular biomarkers to define subsets of tumors that will respond to epigenetic therapies.
EZH2 inhibitors
As outlined above, EZH2 represents an attractive target for chemical inhibition due to its role in silencing, overexpression and mutation in cancer. S-adenosyl-L-methionine (SAM) is considered the universal methyl donor for catalytic reactions of histone methyltransferases (HMTs). To date, clinically relevant inhibitors of EZH are all SAMcompetitive small molecules.
EPZ 6438 and GSK 2816126 are considered pharmacologically improved EZH2 inhibitors with low nanomolar range affinity and a higher selectivity for EZH2 than previously described inhibitors [186, 187] . Both of these small molecules are being tested in Phase I clinical trials against hematopoietic malignancies. Because all HMTs require SAM for enzymatic activity, the likelihood for off-target effects might be high, but this barrier is seemingly one that can be chemically overcome. For example, EZH1, which is 96% identical to EZH2 within the SET domain is inhibited significantly less than EZH2 by GSK 126 (an analog of GSK 2816126), as are 20 other HMTs [186] . Thus, EZH2 inhibitors display a degree of specificity currently lacking in nucleoside analogs. Currently, we are still awaiting the results of clinical trials to provide a clearer picture of their toxicity profile.
Both EPZ 6438 and GSK 126 exhibit cytotoxic and antiproliferative effects on DLBCL cells harboring EZH2 mutations, and decidedly inhibit the growth of EZH2 mutant DLBCL xenografts in mice, albeit at fairly high concentrations (50-80 mg/kg or greater) [186, 187] . In contrast, xenografts with wild-type EZH2 were affected in a limited fashion. It should be noted that in vitro, 50% growth inhibition was generally not reached until a week, or longer, of exposure to EZH2 inhibitors in these same studies. Is such a delay in growth suppression under the ideal conditions of tissue culture a cause to doubt the clinical outcomes of these patient trials? These data also call into question the specificity of the drugs. It would be interesting to compare the antiproliferative effects of these drugs to those observed upon EZH2 knockdown. Mechanistically, the target genes of EZH2 inhibitors, whose repression stimulate a cytotoxic response, are still not well-defined. GSK 126 is known to activate a distinct set of immune-related genes, but it is unclear if these mediate the antiproliferative effects, or even if the promoters of these genes were enriched for H3K27me3 prior to drug exposure [186] . Thus, more work needs to be done to define the precise molecular mechanisms whereby these inhibitors carry out their antitumor effects.
Catalytically activating mutations of EZH2 provide a meaningful biomarker for EZH2 inhibitor sensitivity that is sorely missing with nucleoside analogs. Recent evidence suggests that EZH2 has oncogenic activity beyond its catalytic domain [188] , supporting the idea that next-generation EZH2 inhibitors might focus on dismantling the PRC2 complex. As we now know, silenced tumor suppressors are characterized by a number of changes to the epigenome. Thus, targeting multiple pathways that contribute to silencing might be a more powerful approach to epigenetic therapies. Not surprisingly, many preclinical studies show profound synergy between epigenetic drugs [189] [190] [191] , and we suggest that such combinations likely represent the most potent approach to epigenetic therapy.
Histone deacetylase inhibitors
Lysine acetylation is a covalent post-translational modification mediated by lysine acetyltransferases (KATs). Historically, the first acetylated proteins to be identified were histones, but since that time hundreds of other acetylated proteins have been identified [192] . Lysine acetylation is a reversible modification mediated by four classes of lysine deactylases (KDACs). While both KAT and KDAC activities are predominantly nuclear, it is now widely accepted that lysine acetylation and its removal is an important protein regulatory mechanism within the cytoplasmic compartment as well [193, 194] . Pharmacological inhibitors of KDAC activity (KDACi) have been extensively tested in clinical trials and overall, the favorable responses have been more pronounced against hematopoietic malignancies than solid tumors. An exciting advance in this field is the finding that patients with several hematopoietic malignancies, including cutaneous T-cell lymphoma (CTCL) and multiple myeloma show significant clinical responses to this class of drugs. The pan-KDAC inhibitors vorinostat and romidepsin are now FDA approved for the treatment of relapsed or refractory cutaneous T-cell lymphoma (CTCL). Recently, pabobinostat, another pan-KDAC inhibitor, was FDA approved for the treatment of progressive multiple myeloma. Certainly, a factor in their FDA approval was their favorable toxicity profile. As monotherapy, the primary KDACi toxicities include thrombocytopenia and fatigue, with stronger toxicities including severe thrombocytopenia, or myelosuppression, becoming more apparent when used as combination therapies [195] . In comparison to pabobinostat, vorinostat appears to have a milder toxicity profile [195] . To better understand the anti-tumor activity of these drugs, we should first examine the cellular roles of protein acetylation.
Histone acetylation was the first lysine acetylation event identified, and its functional relevance to the transcriptional process has been broadly studied. Even though histone acetylation was first described over 50 years ago [196] , there is still much to learn regarding the varied effects of this covalent post-translational modification on chromatin structure and transcription. Histone acetylation is enriched in transcriptionally active regions of the genome, especially at proximal promoters and enhancers. Here, acetylation of the N-terminal tail of histones acts on at least two levels to facilitate the binding of transcription factors. First, there is biochemical evidence that N-terminal acetylation loosens contact between core nucleosome proteins and DNA, thereby making transcription factor binding sites more accessible [197, 198] . Likely having a greater influence on transcriptional outcomes is the recruitment of bromodomain proteins. Bromodomain proteins recognize acetylated histones and are actively recruited to enhancer and promoter regions [199] . Bromodomain proteins have diverse functional properties allowing them to modulate transcriptional activity. SMARCA2/4 for example, harbor ATPase chromatin remodeling activity, allowing them to shift or displace nucleosomes, generating DNAse I hypersensitive sites conductive to transcription factor binding [200] . Other bromodomain proteins, such as Brd4, act to enhance transcriptional elongation through Serine 2 phosphorylation of the Pol II C-terminal domain [201] . Still others, such as TAF1, may act to directly recruit Pol II to promoters [202] .
Based on the role of acetylation in promoting transcription, it is not surprising that targeting KDACs to reporter genes leads to a reversible shutdown of transcription, associated with loss of histone acetylation [41] . Thus, it is a reasonable hypothesis that disruption of this pathway might lead to epigenetic silencing of TSGs. As described above, epigenetic silencing of TSGs is associated with a number of epigenetic events, but it is uncertain that local KDAC activity leads to further epigenetic alterations commonly seen at silenced cancer loci, beyond histone deacetylation. Additionally, there are few reports indicating that deregulation of KDAC activity in cancer cells initiates irreversible epigenetic silencing, and overall it seems unlikely that aberrant KDAC activity leads to TSG silencing in cancer. In contrast to a role for initiation of TSG silencing, restoring histone acetylation through pharmacologic inhibition of KDAC clearly reactivates the expression of a subset of silenced TSGs including the classic TSGs CDKN2A ARF or SFRP-1 [203, 204] .
KDACi also act in synergy with DNA methylation inhibitors to restore the expression of TSGs showing highly methylated promoters, indicating a role for KDACs in the maintenance of gene silencing. It is through the reactivation of silenced TSGs that KDACi are generally thought to exert their anti-cancer activity. A closer examination of the studies using KDACi to restore gene expression provides valuable insights into both the biology of KDACs, the therapeutic potential of KDAC inhibitors, while raising new questions concerning their mode of action. TSGs having promoter methylation are generally regarded as being irreversibly silenced. There are numerous reports indicating that KDACi are unable to reactivate methylated TSGs, especially when drug exposure is limited to a 24 hr exposure [205] [206] [207] . However, longer exposures do lead to reactivation of methylated genes, but this effect may not be direct. Long exposures to KDACi suppress the expression of DNMT1 and DNMT3b, resulting in genome-wide hypomethylation [208, 209] . Thus, it is entirely possible that reactivation of silenced TSGs by KDAC inhibitors is a direct consequence of the loss of these two critical DNMTs. This concept is controversial, and recent reports indicate KDACi may indeed restore epigenetically silenced TSGs, albeit transiently, without altering DNA methylation profiles [204, 210] . Further work will be required to decipher the precise epigenetic landscape of endogenous, silenced, TSGs that is conducive to reactivation by KDAC inhibition.
Beyond DNA methylation, histone acetylation has a complex relationship with other histone modifications. For example, KDACi cause widespread histone hyperacetylation as expected, but secondary changes to the post-translational modification profile of histones can also be observed. For example, a global increase in both the transcriptional activating mark, H3K4me3 is observed after exposure to KDACi [211] . In stark contrast, the EZH2-directed repressive mark H3K27me3 accumulates at proximal promoter regions across the genome even after exposures of just 1 hr to clinically relevant KDACi [212] . These seemingly paradoxical epigenetic changes make it challenging to predict whether KDACi should have a stronger influence on transcriptional activation or repression. In light of these complex epigenetic changes imparted by KDACi, it might come as no surprise that transcriptome profiling reveals a nearly equivalent number of genes down-regulated by KDACi as those up-regulated [213, 214] . Notably, in CTCL, where KDACi are FDA approved as a therapeutic intervention, exposure to the KDAC panobinostat led to a striking decrease in gene expression profiles, with comparatively fewer genes being up-regulated [215] .
To date, biomarkers to predict patient cohorts that will respond to KDACi are lacking in both CTCL and myeloma. Considering that the response rate to CTCL is less than 35%, biomarkers seem critical to identify the responsive cohort [216] . Such predictive biomarkers may also help expand the treatable population beyond CTCL and myeloma and may facilitate the identification of complimentary pathways that may be targeted in synergy with KDACi. Perhaps looking at the other activities of KATs (and by association KDACs) beyond the regulation of transcription might provide insights into the anti-cancer properties of KDACi and facilitate the discovery of new biomarkers.
A global survey of proteins losing acetylation after exposure to a broad range of KDACs using mass spectrometry predicted between 20% and 60% of proteins acted upon by KDACi were localized in the cytoplasm [217] . Consistent with this, recent work has greatly expanded the role of KATs beyond modulation of transcription. In the nucleus, this includes a critical role in response to damaged DNA [218] . In the cytoplasm, acetylation of mitochondrial proteins regulates respiration [219] , and protein acetylation plays key roles in autophagy and organization of the cytoskeleton [194] . Importantly, there is evidence that some of these non-transcriptional processes, such as autophagy, may dictate cell sensitivity to KDACi [220, 221] .
In sum, it is clear that KDACi have great clinical potential, and there are opportunities for improvement. First, we must stop thinking of KDACi as merely transcriptional regulators. We must broaden our studies to examine their impact on other processes modulating proliferation and survival. Such studies will help reveal the critical pathways modulated by KDAC inhibition that mediate its anti-cancer properties thereby expediting the discovery of predictive biomarkers for this class of compounds.
Future perspectives and alternatives
A major goal of future research will be to decipher how the extracellular environment, and oncogenic events in the cytoplasm, communicate to the nucleus, to rearrange normal epigenetic programming. For example, how does RTK mutation lead to specific DNA methylation profiles? Or, vice versa, do epigenetic alterations facilitate the acquirement of particular genetic aberration? Beyond genetic drivers of oncogenesis, it is well-established that a variety of environmental carcinogens confer reproducible changes to DNA methylation patterns [222] [223] [224] . It will be worthwhile to investigate whether carcinogens may carry out such reprogramming, at least in part, through one of the five mechanisms described above.
It will also be of interest to determine whether the mechanisms of silencing described within this review work independently of one another, or conversely, and more likely in our opinion, multiple silencing networks act cooperatively to irreversibly shut down transcription. Studies providing mechanistic insights into how the dysfunction of a single epigenetic factor leads to reprogramming of a spectrum of epigenetic marks would also contribute invaluable information to the field. It will also be of great interest to examine whether the activity of TET demethylases have an impact on the expression of TSGs.
We are confident that future studies will indeed answer such grandiose questions. The advent of high throughput sequencing technologies has provided researchers with exciting opportunities to probe tumors and cell lines for epigenomic reprogramming thereby answering questions that were previously unattainable. Such high throughput sequencing capabilities and the introduction of the CRISPR/Cas9 system for genomic editing will undoubtedly allow us to define mechanisms whereby tumor suppressor genes are silenced in the coming years.
From a therapeutic perspective, future work both in the lab and clinic will need to sort out whether targeting epigenetic events nonspecifically, such as with 5-Aza-2-deoxycytidine, is a less effective approach than precision medicine targeting epigenetic regulators, such as BET inhibitors. The future may also hold the promise of editing the genome within tumors in order to restore the expression of tumor suppressor genes, without further alterations to the genome. Overall, it is clear that basic, biochemical analysis of our epigenome is being translated into exciting new therapies for multiple diseases.
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